Six Compounds Cleared an FDA Panel. Nothing Became Legal.
What the July advisory vote actually changed — and where it leaves your clinic exposed.
Since July 24, we have had the same conversation a dozen times.
A clinic owner forwards us a headline. Sometimes it came from a supplier’s email blast, sometimes from a patient. The takeaway is always the same: the FDA cleared six peptides, compounding is back, time to rebuild the menu.
We understand the excitement. We also need to be direct with you, because the gap between what happened and what people believe happened is the widest we have seen in this industry — and it is exactly the kind of gap that turns into a compliance problem.
Here is what actually happened.
What the committee did
On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee met to consider whether seven peptides should be added to the 503A Bulks List — the list of bulk substances compounding pharmacies are permitted to use.
The committee recommended six of the seven. It narrowly rejected the last one.
Two details most coverage skipped.
First, the votes were close. Three passed 8–6 with an abstention. Another cleared 7–5 with two abstentions. The rest went through by similar margins, and the rejection came down to a single vote.
Second, and more significant: FDA’s own scientific staff had recommended against adding any of the seven. The panel voted against its own agency.
What the committee did not do
An advisory committee recommendation is advice. It is not an agency action.
It did not add anything to the 503A Bulks List. It did not approve any peptide. It did not give a single pharmacy authority to compound a single vial.
Placement on that list requires the FDA to accept the recommendation and then complete formal public rulemaking, a process that takes time and has not happened. Nothing about what a pharmacy may legally compound changed in July.
Most of the confusion comes from collapsing three separate events into one:
- Removal from Category 2 — a procedural step earlier this year. Did not authorize anything.
- A PCAC recommendation — July. Not binding. This is where we are.
- Actual placement on the compoundable list after rulemaking — has not happened.
Only the third changes what a pharmacy may legally make.
Where this leaves your clinic exposed
This is the part we want you to sit with.
Your marketing language. If any page, flyer, ad, menu or email of yours now says “FDA approved,” “newly cleared,” “now legal,” or anything a reasonable patient would read that way, that is a problem — and it is one you created after July 24, which makes it harder to explain later. Some suppliers are circulating copy that clinics are reusing. Read it before you publish it.
Your front desk. Patients are reading the same headlines. The first person they ask is usually the least-trained person in the building. Role-appropriate training for every member of staff, clinical and non-clinical, is what prevents misinformation and protects scope of practice — and it is a documented requirement, not a nice-to-have.
Your sourcing assumptions. A recommendation does not legitimize a supplier. Anyone treating this vote as a reason to relax sourcing standards has it precisely backwards.
Your state. Federal and state tracks are separate. Your state medical board sets its own advertising standards, and those apply to you regardless of what happens federally. A future federal listing would not automatically change what your board expects of you.
Your consent forms. If your consent language was written to describe an unapproved compound, it is still accurate — and it should stay that way. Do not let anyone soften it in response to a headline.
What we would do this month
- Audit your language. Every patient-facing surface: website, flyers, menus, intake, ads, and any supplier copy you have reused. Anything implying approval comes down this week.
- Brief your team. Fifteen minutes and one script: what the vote was, what it was not, and where to route the question when it comes.
- Check consent and intake. Confirm both still describe these compounds accurately, and leave that language alone.
- Watch for round two. A second advisory meeting is expected by February 2027, covering five further compounds. The same wave of confusion will arrive again. Be ready for it that time.
The bigger picture
We are not pessimistic about this. A panel voting to bring widely used compounds into a regulated framework is, directionally, good for clinics that want to do this properly. Oversight beats a grey market.
But the clinics that get hurt in a moment like this are never the cautious ones. They are the fast ones — the clinics that rewrote the website the same week on the strength of a headline, and now have to explain why.
This category is going to keep moving. Your job is to make sure your program is built on what is actually true today, and structured well enough to absorb whatever is true next year.
Start free on the Aura Discovery portal.
Start freeIncludes the Peptide Cheat Sheet, free on the Discover tier.
These services are for wellness optimization and educational purposes only. Products are not approved by the FDA to diagnose, treat, cure, or prevent any disease.
This article is educational and reflects the regulatory picture as of publication. It is a compliance framework, not legal advice. Confirm your own obligations with qualified healthcare counsel, your medical director, and your state board.